Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Grand Enterprises in Talks to Acquire Sinclair, a $156 Million UK Company

publication date: Jul 5, 2018

China Grand Enterprises, an investment firm, together with its affiliate Huadong Medicine are in early stage talks to acquire Sinclair Pharma, a UK aesthetics company. Sinclair climbed 23.5% on the news, raising its market capitalization to $156 million. Based on its collagen stimulation technology, Sinclair offers a variety of minimally invasive, long-duration fillers and smoothers for the skin. Under British rules, China Grand has 30 days to strike a final deal for Sinclair. More details....

Stock Symbols: (SHZ: 000963) (L: SPH)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.